Erin E. Cawston
YOU?
Author Swipe
View article: Global multi‐specialty clinician perspectives on the implementation of Alzheimer's disease blood biomarkers
Global multi‐specialty clinician perspectives on the implementation of Alzheimer's disease blood biomarkers Open
INTRODUCTION Clinicians’ views on the clinical readiness of Alzheimer's disease (AD) blood biomarkers (BBMs) are not well understood. METHODS The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment B…
View article: Examining the relationship between plasma pTau181 and cognitive decline, structural brain integrity, and biological ageing in midlife
Examining the relationship between plasma pTau181 and cognitive decline, structural brain integrity, and biological ageing in midlife Open
INTRODUCTION Although plasma pTau181 has been shown to accurately discriminate patients with Alzheimer’s disease from healthy older adults, its utility as a preclinical biomarker in middle-aged community-based cohorts is unclear. METHODS P…
View article: Midlife physical activity and amnestic MCI: Impact on hippocampal volume
Midlife physical activity and amnestic MCI: Impact on hippocampal volume Open
Background The projected doubling of dementia prevalence by 2050 highlights the critical importance of altering the dementia trajectory and associated burden. Modifiable risk factors account for 40% of dementia risk (Livingston et al, 2020…
View article: The New Zealand‐Dementia Prevention Research Clinics: Plasma biomarkers and the Alzheimer’s disease continuum
The New Zealand‐Dementia Prevention Research Clinics: Plasma biomarkers and the Alzheimer’s disease continuum Open
Background Single molecule array (Simoa) technology enables the detection of Alzheimer’s disease (AD) neuropathology in blood. This study compared cross‐sectional biomarker profiles for participants from the New Zealand‐Dementia Prevention…
View article: Developing blood-brain barrier arterial spin labelling as a non-invasive early biomarker of Alzheimer’s disease (DEBBIE-AD): a prospective observational multicohort study protocol
Developing blood-brain barrier arterial spin labelling as a non-invasive early biomarker of Alzheimer’s disease (DEBBIE-AD): a prospective observational multicohort study protocol Open
Introduction Loss of blood-brain barrier (BBB) integrity is hypothesised to be one of the earliest microvascular signs of Alzheimer’s disease (AD). Existing BBB integrity imaging methods involve contrast agents or ionising radiation, and p…
View article: DEveloping BBB-ASL as non-Invasive Early biomarker of Alzheimer's Disease (DEBBIE-AD): Study design
DEveloping BBB-ASL as non-Invasive Early biomarker of Alzheimer's Disease (DEBBIE-AD): Study design Open
Introduction: Arterial spin labeling (ASL) MRI, a non-invasive technique for imaging perfusion, now allows studying BBB permeability. The DEveloping BBB-ASL as a non-Invasive Early biomarker of Alzheimer's Disease (DEBBIE-AD) multi-cohort …
View article: Plasma biomarkers across the Alzheimer’s disease continuum in the New Zealand‐Dementia Prevention Research Clinics
Plasma biomarkers across the Alzheimer’s disease continuum in the New Zealand‐Dementia Prevention Research Clinics Open
Background Advances in ultra‐sensitive immunoassay methods, like Single molecule array (Simoa) technology, show that Alzheimer’s disease (AD) neuropathology can be detected in blood at the earliest stages of AD. This study compared cross‐s…
View article: Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer’s disease in Aotearoa, New Zealand
Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer’s disease in Aotearoa, New Zealand Open
Aotearoa New Zealand's population is ageing. Increasing life expectancy is accompanied by increases in prevalence of Alzheimer's Disease (AD) and ageing-related disorders. The multicentre Dementia Prevention Research Clinic longitudinal st…
View article: Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis
Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis Open
View article: Gα<sub>s</sub>signalling of the CB<sub>1</sub>receptor and the influence of receptor number
Gα<sub>s</sub>signalling of the CB<sub>1</sub>receptor and the influence of receptor number Open
Background and Purpose CB 1 receptor signalling is canonically mediated through inhibitory Gα i proteins, but occurs through other G proteins under some circumstances, Gα s being the most characterized secondary pathway. Determinants of th…
View article: Identification of<i>N</i>‐arachidonoyl dopamine as a highly biased ligand at cannabinoid CB<sub>1</sub>receptors
Identification of<i>N</i>‐arachidonoyl dopamine as a highly biased ligand at cannabinoid CB<sub>1</sub>receptors Open
Background and Purpose N ‐arachidonyl dopamine (NADA) has been identified as a putative endocannabinoid, but there is little information about which signalling pathways it activates. The purpose of this study was to identify the signalling…
View article: Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors
Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors Open
ORG27569 (1) is an allosteric modulator of CB1. 1 produces a distinct cAMP temporal fingerprint with complex time-dependent modulation of agonist-mediated responses. The aim of this study was to characterize the cAMP signaling response of …